诺泰生物(688076) - 2023 Q1 - 季度财报

Financial Performance - In Q1 2023, the company reported a net profit of ¥18,885,415.84, an increase from ¥14,993,326.89 in Q1 2022, representing a growth of approximately 25.6%[12] - Basic earnings per share for Q1 2023 was reported at ¥0.10, up from ¥0.08 in Q1 2022, indicating a growth of 25%[12] - The company’s operating profit for the quarter was ¥23,528,055.19, compared to ¥14,930,312.73 in the same period last year, reflecting a significant increase of about 57.5%[12] - The net profit attributable to shareholders of the listed company for Q1 2023 was RMB 21,012,921.56, reflecting a 30.56% year-on-year growth[30] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 23,382,586.67, which is an increase of 84.35% year-on-year[30] - The net profit after deducting non-recurring gains and losses surged by 84.35% due to increased sales revenue[42] Assets and Liabilities - The total assets as of March 31, 2023, amounted to ¥2,592,700,235.07, compared to ¥2,522,299,186.67 at the end of 2022, indicating an increase of about 2.8%[10] - The total liabilities rose to ¥648,695,474.24 from ¥597,412,479.77, marking an increase of about 8.6%[10] - The total equity attributable to shareholders increased to ¥1,931,471,658.69 from ¥1,910,226,099.04, representing a growth of approximately 1.1%[10] - The total non-current assets reached RMB 1,502,113,796.17, compared to RMB 1,469,829,602.50 in the previous year[36] - The total liabilities for the company were RMB 604,120,687.19, an increase from RMB 551,323,149.93 in the previous year[36] Cash Flow - The company's cash and cash equivalents increased to ¥478,034,709.32 from ¥399,964,705.79 year-over-year, reflecting a growth of approximately 19.5%[9] - The net cash flow from operating activities for Q1 2023 was RMB 144,720,177.89, showing a significant increase of 9,897.52% compared to the previous year[30] - Cash flow from operating activities amounted to CNY 144,720,177.89, significantly up from CNY 1,447,560.62 in the previous period[50] - Net cash inflow from operating activities was CNY 308,976,823.93, compared to CNY 144,960,960.65 in the previous year[50] - The net increase in cash and cash equivalents was $94,551,033.29, contrasting with a decrease of $37,593,550.63 in the previous year[61] Revenue and Expenses - The company's total operating revenue for Q1 2023 was RMB 208,058,681.69, representing a 54.98% increase compared to the same period last year[30] - Operating revenue for the period was CNY 208,058,681.69, a 54.98% increase year-on-year[48] - Research and development expenses totaled CNY 20,884,102.29, representing a 59.59% increase[42] - Research and development expenses accounted for 10.04% of operating revenue, up 0.29 percentage points[41] Shareholder Information - The company has a total of 10,609 shareholders at the end of the reporting period[32] - The weighted average return on equity rose to 1.09%, an increase of 0.21 percentage points[41] Other Financial Activities - The company reported a loss of RMB 5,502,004.42 from the disposal of a waste warehouse during the reporting period[30] - The company received government subsidies amounting to RMB 2,731,880.44, which are closely related to its normal business operations[30] - The company has no reported financing or margin trading activities among its top shareholders[7] - There were no mergers or acquisitions reported during the period, with no net profit from merged entities[13] - Cash inflow from investment activities totaled $106,461,541.49, down from $212,512,573.97 year-over-year[61] - Cash outflow for investment activities was $252,391,749.91, compared to $315,912,070.61 in the previous period[61] - Net cash flow from investment activities was -$145,930,208.42, worsening from -$103,399,496.64 year-over-year[61] - Cash inflow from financing activities increased to $155,000,000.00, up from $82,700,000.00 in the previous period[61] - Cash outflow for financing activities was $59,236,521.22, compared to $18,190,587.09 last year[61] - Net cash flow from financing activities improved to $95,763,478.78, compared to $64,509,412.91 in the previous period[61]